September 1st, 2013
Inside the ACCOAST Trial of Pretreatment Prasugrel
Gilles Montalescot, MD, PhD, John Ryan, MD, Richard A. Lange, MD, MBA and L. David Hillis, MD
Gilles Montalescot, lead investigator of the ACCOAST trial, discusses why prasugrel pretreatment did not benefit patients with non–ST-segment elevation acute coronary syndromes.
NEJM Journal Watch — Recent Cardiology Articles- Extensive Ablation vs. Pulmonary Vein Isolation in Persistent Atrial Fibrillation
- Can a Novel Stent Design Improve Long-Term Outcomes of Percutaneous Coronary Intervention?
- Are Angiographically-Derived Coronary Physiology Measurements Ready for Use in the Cath Lab?
- A Randomized Trial of Transcatheter Edge-to-Edge Repair for Severe Tricuspid Regurgitation
- An Early Look at a Novel Intranasal Loop Diuretic